HC Wainwright Forecasts Sanara MedTech Q1 Earnings

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Sanara MedTech Inc. (NASDAQ:SMTI - Free Report) - Research analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Sanara MedTech in a report released on Monday, August 18th. HC Wainwright analyst Y. Chen forecasts that the company will earn ($0.22) per share for the quarter. HC Wainwright has a "Buy" rating and a $54.00 price target on the stock. The consensus estimate for Sanara MedTech's current full-year earnings is ($1.10) per share. HC Wainwright also issued estimates for Sanara MedTech's Q2 2026 earnings at ($0.21) EPS, Q3 2026 earnings at ($0.21) EPS and Q4 2026 earnings at ($0.20) EPS.

Sanara MedTech Price Performance

Sanara MedTech stock opened at $31.58 on Tuesday. Sanara MedTech has a 12 month low of $23.53 and a 12 month high of $39.08. The stock's 50 day moving average is $27.72 and its 200-day moving average is $30.38. The company has a current ratio of 2.26, a quick ratio of 2.03 and a debt-to-equity ratio of 1.25. The company has a market capitalization of $281.06 million, a price-to-earnings ratio of -27.22 and a beta of 1.26.

Sanara MedTech (NASDAQ:SMTI - Get Free Report) last posted its earnings results on Wednesday, August 13th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.10. Sanara MedTech had a negative return on equity of 26.43% and a negative net margin of 10.22%. The company had revenue of $25.83 million for the quarter, compared to the consensus estimate of $25.15 million.

Hedge Funds Weigh In On Sanara MedTech

Institutional investors and hedge funds have recently made changes to their positions in the company. GAMMA Investing LLC grew its position in shares of Sanara MedTech by 8,423.8% in the first quarter. GAMMA Investing LLC now owns 1,790 shares of the company's stock valued at $58,000 after purchasing an additional 1,769 shares during the last quarter. Wells Fargo & Company MN grew its position in Sanara MedTech by 53.9% during the fourth quarter. Wells Fargo & Company MN now owns 1,893 shares of the company's stock worth $63,000 after buying an additional 663 shares in the last quarter. MetLife Investment Management LLC acquired a new stake in Sanara MedTech during the first quarter worth approximately $82,000. Lazard Asset Management LLC grew its position in Sanara MedTech by 63,100.0% during the second quarter. Lazard Asset Management LLC now owns 3,160 shares of the company's stock worth $89,000 after buying an additional 3,155 shares in the last quarter. Finally, BNP Paribas Financial Markets acquired a new stake in Sanara MedTech during the fourth quarter worth approximately $106,000. Institutional investors and hedge funds own 8.10% of the company's stock.

About Sanara MedTech

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.